Product Description
YKST02, developed by Excyte, is a bispecific antibody with a 2+2 symmetric structure based on the company’s unique fusion of IgG and scFv technology (FIST) platform. It is positioned to be a best-in-class drug for multiple myeloma patients, utilizing the same mechanism of action as BCMA-targeting CAR-T therapy. Preclinical data shows that YKST02 is safer and more effective than Teclistamab from J&J. The Investigational new drug (IND) application was submitted to the Center for drug evaluation (CDE) of National Medical Product Administration (NMPA) China on February 26, 2024, and approved within two months, demonstrating the sufficiency of the preclinical study data for clinical trials. It is an anti-CD3×BCMA. (Sourced from: http://www.iexcyte.com/news/shownews.php?id=189&lang=en)
Mechanisms of Action: BCMA Inhibitor,CD3 Inhibitor
Novel Mechanism: No
Modality: Bispecific Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Excyte Biopharma Ltd
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Multiple Myeloma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| YKST02-I-01 | P1 |
Recruiting |
Multiple Myeloma |
2026-12-31 |